]>
IRCT20250711066450N1 IRCT 2026-07-09 Zanjan University of Medical Sciences Investigating the effect of telmisartan in comparison with valsartan and losartan in patients with diabetic nephropathy Investigating the effect of telmisartan in comparison with valsartan and losartan in the amount of albuminuria in patients with diabetic nephropathy 2025-08-22 anticipated 152 Complete https://irct.ir/trial/84890 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be randomly allocated to one of four study groups (telmisartan, losartan, valsartan, or control) using block randomization with a 1:1:1:1 allocation ratio. The random allocation sequence will be generated using Random Allocation Software with a block size of four. The unit of randomization is the individual eligible participant. To ensure allocation concealment, the randomization sequence will be prepared by a person who is not involved in participant recruitment or outcome assessment. The allocation sequence will be kept in sequentially numbered, opaque, sealed envelopes (SNOSE). After confirming eligibility and obtaining written informed consent, the next envelope in sequence will be opened to determine the participant's treatment allocation. The person generating the randomization sequence will have no role in participant enrollment or outcome assessment. 3 Diabetic nephropathy. Intervention 1: Intervention group1: Telmisartan tablets 40 mg(Actoveerco Pharmaceutical Company) daily for 3 months. Intervention 2: Intervention group2: Losartan tablets 25 mg(Actoveerco Pharmaceutical Company) daily for 3 months. Intervention 3: Intervention group3: Valsartan tablets 40 mg (Actoveerco Pharmaceutical Company)daily for 3 months. Intervention 4: Control group: Participants in the control group will not receive any of the study medications (telmisartan, losartan, or valsartan) during the 3-month study period. They will continue their routine standard care, including antidiabetic medications and other usual treatments as prescribed by their treating physician. Blood pressure, serum creatinine, HbA1c, and the urinary albumin-to-creatinine ratio (UACR) will be measured at baseline and at the end of the study and compared with the intervention groups. Yes - There is a plan to make this available What will be shared: All data can be shared after the study is completed and individuals are de-identified. When: Access period starts 6 months after results are published. To whom: Researchers working in academic and scientific institutions Conditions: The documents will be usable with reference to the source and the study direction. Where to obtain: Email address mohammad68.n121@gmail.com Mohammadli shahmoradi How to obtain: After sending the email to the researcher, she will immediately receive the documentation. Comments:
public Mohammadali Shamoradi
No 155, Parvin Etesami blvd, Vahidie town
Zanjan Iran (Islamic Republic of) 4515844183 +98 24 3313 0001 Mohammad68.n121@gmail.com Zanjan University of Medical Sciences scientific Mohammadali Shahmoradi
No155,parvin etesami blvd,vahidieh town
Zanjan Iran (Islamic Republic of) 4515844183 +98 24 3313 0001 Mohammad68.n121@gmail.com Zanjan University of Medical Sciences Iran (Islamic Republic of) History of type 2 diabetes for more than 5 to 10 years hemoglobin A1c ≤10% GFR>60 >30first-morning spot UAC<300 30 years 70 years Both Pregnant women Presence of kidney disease unrelated to diabetes CHF CVA chronic liver disease prostatic diseases diabetes type 1 immunodeficiency diseases E11.21 Type 2 diabetes mellitus with diabetic nephropathy Treatment - Drugs Treatment - Drugs Treatment - Drugs N/A Intervention group1: Telmisartan tablets 40 mg(Actoveerco Pharmaceutical Company) daily for 3 months Intervention group2: Losartan tablets 25 mg(Actoveerco Pharmaceutical Company) daily for 3 months Intervention group3: Valsartan tablets 40 mg (Actoveerco Pharmaceutical Company)daily for 3 months Control group: Participants in the control group will not receive any of the study medications (telmisartan, losartan, or valsartan) during the 3-month study period. They will continue their routine standard care, including antidiabetic medications and other usual treatments as prescribed by their treating physician. Blood pressure, serum creatinine, HbA1c, and the urinary albumin-to-creatinine ratio (UACR) will be measured at baseline and at the end of the study and compared with the intervention groups. Albuminuria rate in patients with diabetic nephropathy. Timepoint: Before the start of the intervention and at the end of the third month after the intervention. Method of measurement: urine albumin. Serume Creatinine. Timepoint: Before the intervention and at the end of the third month of the intervention. Method of measurement: serume Creatinine. Zanjan University of Medical Sciences Approved 2025-06-30 Ethics Committee of Zanjan University of Medical Sciences Zanjan University of Medival SciEnces, Jomhouri street, Azadi square, Etemadieh town Zanjan Zanjan Iran (Islamic Republic of)